The earnings call presented a mixed outlook. While there were notable achievements in revenue growth, operational improvements, and strategic refocus on LineaRx, the exit from a business segment, workforce reduction, and ongoing financial challenges cast a shadow on the overall performance.

Company Guidance -

Q4 2025

During the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results call, significant guidance was provided regarding the company's strategic restructuring and financial performance. The company reported total revenues of $1.2 million for the first quarter, a notable increase from $891,000 in the same period of fiscal 2024. This growth stemmed from higher product revenue in the DNA tagging business and increased isotopic testing services revenue. However, the operating loss improved to $3 million from $3.8 million in the previous year, attributed to reduced selling, general, and administrative costs. A net loss of $2.7 million was recorded, compared to a $1.1 million loss in the prior year, due to an unrealized gain on the change in the fair value of warrants. The cash and cash equivalents as of December 31st stood at $9.3 million. The company also highlighted a strategic pivot to focus on its LineaRx subsidiary, exiting the DNA tagging segment and reducing the workforce by approximately 20%. This restructuring aims to optimize the cost structure and capitalize on the growing demand for synthetic DNA manufacturing, setting the stage for improved shareholder value and future growth opportunities.

Increased Revenue

Total revenues for the first quarter of fiscal 2025 were $1.2 million, compared with $891,000 for the same period of fiscal 2024. This increase was driven by higher product revenue from DNA tagging and increased isotopic testing services.

Reduction in Operating Loss

Operating loss for the first quarter was $3 million, compared with $3.8 million in the prior year period, due to lower selling, general, and administrative costs.

GMP Site Certification

Certification of the GMP Site One facility has been completed, allowing for the production of DNA at scale.

Strategic Focus on LineaRx

The company has restructured to focus on the LineaRx subsidiary, aiming to capitalize on the growing demand for enzymatically produced DNA.

LineaRx Customer Growth

In fiscal 2024, LineaRx engaged over 25 customer projects, with expectations for multiple projects to enter the clinic in 2025.

Launch of New Product - Linea Donor DNA

Linea Donor DNA is a high-fidelity DNA form optimized for CRISPR gene editing, available for research use, with GMP availability targeted for later in the year.

Applied DNA Sciences (APDN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

APDN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 11, 2025	2025 (Q4)	- / -	-240	―	―	―
Aug 07, 2025	2025 (Q3)	-37.50 / -	352.5	―	―	―
May 15, 2025	2025 (Q2)	-45.00 / -230.25	-3982.5	94.22% (+3752.25)	―	―
Feb 13, 2025	2025 (Q1)	- / -420.00	-1350	68.89% (+930.00)	―
Dec 17, 2024	2024 (Q4)	-255.00 / -240.00	-3900	93.85% (+3660.00)	―	―
Aug 08, 2024	2024 (Q3)	-371.25 / 352.50	-3600	109.79% (+3952.50)
May 10, 2024	2024 (Q2)	-3375.00 / -3982.50	750	-631.00% (-4732.50)	―	―
Feb 08, 2024	2024 (Q1)	-4650.00 / -1350.00	-4500	70.00% (+3150.00)
Dec 07, 2023	2023 (Q4)	-3975.00 / -3900.00	-1111.575	-250.85% (-2788.43)	―
Aug 10, 2023	2023 (Q3)	-3600.00 / -3600.00	-1950	-84.62% (-1650.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

APDN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.18	$4.23	+1.20%
May 15, 2025	$12.15	$10.05	-17.28%
Feb 13, 2025	$130.65	$127.58	-2.35%
Dec 17, 2024	$172.50	$174.67	+1.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Applied DNA Sciences (APDN) report earnings?

Applied DNA Sciences (APDN) is schdueled to report earning on Dec 11, 2025, After Close (Confirmed).

What is Applied DNA Sciences (APDN) earnings time?

Applied DNA Sciences (APDN) earnings time is at Dec 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is APDN EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing